MedCity Influencers

It’s the End Of the Line for One‑Size‑Fits‑All Weight Loss

Instead of viewing obesity as one uniform condition, experts now recognize that it can arise from multiple biological patterns. Understanding that difference could finally change how we approach treatment altogether. 

Fat Asian woman want to lose weight with a centimeter Shape up healthy stomach muscle and diet measuring waist with measure tape after diet weight control obesity weight loss

One evening, my wife and I stumbled upon Fit for TV: The Reality of the Biggest Loser, a documentary that pulled back the curtain on the reality show that turned weight loss into a televised competition. What began as a celebration of rapid transformation through contestants’ willpower became a study in relapse and frustration. Contestants who once embodied “success” now speak of metabolic slowdown, relentless hunger, and inevitable weight regain. The show’s central promise, that discipline and deprivation could permanently reprogram the body, was revealed as fiction. The contestants hadn’t failed the program; the program failed them.

That documentary captures a misunderstanding that still shapes how medicine and society view obesity: we treat it as a single condition with a single cause. But what looks like the same problem from the outside can have entirely different drivers underneath. Environment and behavior matter, but our genes often decide whether lost pounds stay off or come rushing back. 

Over the past decade, scientists and clinicians have gained a clearer understanding of why that happens. Instead of viewing obesity as one uniform condition, experts now recognize that it can arise from multiple biological patterns, such as differences in how appetite is regulated, how the body stores fat, how metabolism adapts, and how cardiometabolic risk shows up from person to person. These variations help explain why the same diet, exercise plan, or medication can work remarkably well for one person and have little effect, or even the opposite effect, in someone else.

presented by

Here’s the truth: two people with the same BMI may share a label but not the same disease. Understanding that difference could finally change how we approach treatment altogether. 

From generic advice to precise biology

For decades, obesity care has revolved around calorie balance, lifestyle change, and medication, as if everyone’s body would respond the same way once the numbers added up.  But if obesity reflects multiple biological drivers, treatment must follow biology, not convention.

For the millions who have tried everything and blamed themselves, that realization alone can be life-changing. The promise of emerging science is personalization: matching the right intervention to the right person at the right time. In the future, one might wonder if a clinician could identify a patient’s individual need before recommending any diet, drug, or exercise plan, ensuring that care is precise rather than guesswork. 

The rise of GLP-1 medications, paired with breakthroughs in genomics and brain science, is transforming how we think about obesity. These drugs act on appetite and metabolic pathways, targeting the biological mechanisms that drive weight gain rather than simply demanding more willpower. Their potential is remarkable, yet public discussion often misses the science, swinging between hype and deep suspicion. A clearer view of biology can ground the conversation in evidence and help explain who benefits, why, and how treatment is evolving.

Matching treatment to biology

Recognizing obesity as a result of individual biology changes how we think about care. The old advice to eat less and move more was never wrong, but for many people, it was incomplete.  Understanding the mechanisms driving someone’s weight can help clinicians tailor treatment plans with far greater precision for each individual.

Consider two patients with identical BMIs. One, who is experiencing appetite dysregulation,  might respond best to behavioral therapy, cognitive approaches, or medications that influence hunger signals in the brain. Conversely, a patient whose obesity is dominated by insulin resistance might respond better to GLP-1 agonists or medications that improve insulin sensitivity. Same diagnosis, different mechanisms, and now, very different solutions.

This is what precision medicine might look like in obesity care. If future care reflects a patient’s underlying biology rather than a single BMI measure, interventions become more targeted, side effects might lessen, and the conversation between patient and clinician becomes more collaborative. Seeing obesity through this lens allows it to be treated with the same precision and respect as any other complex disease.

What it takes to get there

Bringing personalized care into practice will take more than new medications or biological insight. It requires a shift in mindset: from quick fixes to continuous care, and from judgment to understanding. Many people living with obesity already face shame and frustration in the exam room; meeting them with curiosity and empathy can be as transformative as any therapy.

As clinicians begin to integrate more science into everyday practice of obesity management, pharmacologic and behavioral treatments could become more aligned with each patient’s individual biology — relying on evidence instead of trial and error. Longitudinal and virtual care models can extend that precision beyond office visits, creating continuity and support over time.

As this field matures, health systems have a responsibility to keep pace with the science and move past outdated ideas about willpower. Recognizing the biology behind obesity is an opportunity. When care honors that complexity, patients receive something that has been missing for decades: treatment that is both precise and humane.

A fair fight

Watching that old reality show, it was easy to feel pity for the contestants who fought so hard to lose weight, only to regain it. Today, I hope we all can see their stories differently. They weren’t lacking discipline; they were living proof of how biology can overpower even the most determined effort. 

With new science and a more precise understanding of obesity’s many faces, we might have a chance to give future patients something those contestants never had: a fair fight with their own biology.

Photo: kelvn, Getty Images

Dr. Akl Fahed is a Harvard-based cardiologist and scientist, and co-founder and Chief Medical and Scientific Advisor of Goodpath, a virtual provider delivering integrative care for chronic conditions. He shapes the company’s evidence-based approach that combines technology, clinical expertise, and whole-person care. Dr. Fahed’s career bridges academic medicine, cutting-edge research, and entrepreneurship, with a focus on improving access to effective, scalable healthcare.

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.